<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103203</url>
  </required_header>
  <id_info>
    <org_study_id>19.51/Infect.19.02</org_study_id>
    <nct_id>NCT04103203</nct_id>
  </id_info>
  <brief_title>Fast Assay for Pathogen Identification - Quasi-Experimental Intervention Study</brief_title>
  <acronym>FAPIC-QE</acronym>
  <official_title>Fast Assay for Pathogen Identification - Quasi-Experimental Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>School of Medicine, University of Zagreb</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Molzym</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIT Austrian Institute of Technology GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BEE Robotics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Warwick</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Claude Bernard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Axo Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The performance and clinical impact of two diagnostic systems will be evaluated using whole
      blood samples that are collected in parallel with samples for blood culture. As the rapid
      diagnostic systems will have the largest impact on severely ill patients (in need of a fast
      diagnosis) with bacterial infection, the evaluation will be performed in patients suspected
      of bacteraemia. During the study the new systems will be used in parallel with routine blood
      cultures. In alternating periods of 1 month, the results of the diagnostic system will be
      communicated to treating physicians (intervention) or not revealed (control). Blood culture
      results will be reported throughout the complete study period. Patients with suspected sepsis
      at the Emergency Department (ED), the department of infectious diseases/nephrology, and the
      department of haemodialysis will be included. In routine care, two blood culture sets (2x2
      bottles) per patient are collected. One extra blood sample (EDTA tube, 9 ml of blood) will be
      sampled for each routine set of blood cultures. In addition, the clinical data of the
      patients will be collected. The samples will be sent to the clinical laboratory where samples
      are tested with the new systems during regular working hours in batches of 8 samples per run
      (2-3 runs per day). On average, 10%-20% of the blood cultures drawn on the presumption of
      bacteraemia yield bacterial pathogens. Previous data show that 13% of patients yield positive
      blood cultures. Thus, in order to collect blood samples of 100 new episodes of bacteraemia
      approximately 1000 patients (2000 blood cultures + 1000 EDTA tubes) have to be collected for
      each system (2000 patients in total). The results of the systems will be used to evaluate the
      clinical utility of the system regarding time to antibiotic treatment change and bacteraemia
      management. The system will be used directly for the diagnosis of patients, resulting in a
      possible change of treatment strategy. However, routine blood culture practices will still be
      done during the whole study period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Quasi-experimental intervention</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median time from specimen collection/arrival in the laboratory until antibiotic regimen change</measure>
    <time_frame>at study completion, 10 months</time_frame>
    <description>Time period between collection of blood cultures until the first change in antibiotic regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median time to appropriate, species-specific antibiotic therapy</measure>
    <time_frame>at study completion, 10 months</time_frame>
    <description>Time period between collection of blood cultures until the first administration of species-specific antibiotic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>at study completion, 10 months</time_frame>
    <description>In-hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to organism identification</measure>
    <time_frame>at study completion, 10 months</time_frame>
    <description>Time period between collection of blood cultures until the time to identification of a causative organism with the new diagnostics and with blood cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to effective therapy</measure>
    <time_frame>at study completion, 10 months</time_frame>
    <description>Time period between collection of blood cultures until the first administration of antibiotic therapy effective againts the causative organism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to optimal therapy</measure>
    <time_frame>at study completion, 10 months</time_frame>
    <description>Time period between collection of blood cultures until the first administration of antibiotic therapy that is optimal for patient recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day all cause mortality</measure>
    <time_frame>at study completion, 10 months</time_frame>
    <description>Number of patients with 30-day all cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length-of-stay</measure>
    <time_frame>at study completion, 10 months</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>at study completion, 10 months</time_frame>
    <description>Length of stay in an Intensive Care Unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Destination at Discharge</measure>
    <time_frame>at study completion, 10 months</time_frame>
    <description>Destination after discharge (home, rehabilitation home, nursing home, ...)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>New diagnostic results NOT available</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. However, results will not be communicated. Only the results of routine blood cultures will be availabtle to the treating physician. No intervention will take place, care is provided according to normal routine practices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New diagnostic results available</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. Results will be communicated via telephone by the consultant microbiologist and the electronic medical file to the treating physician. Results of routine blood cultures will also be available for all patients. Results of the new diagnostics are expected earlier, and the treating physician is able to make an earlier decision in terms of antibiotic therapy if he/she deems it necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PathoRobot/ Patho-Doc Test result</intervention_name>
    <description>Test results of the new diagnostics will be available to the treating physician.</description>
    <arm_group_label>New diagnostic results available</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspicion of sepsis

          -  The drawning of blood cultures

          -  Age &gt;18 years

        Exclusion Criteria:

          -  Children (&lt;18 years)

          -  Patients who are not hospitalized and sent home after ED admission

          -  Duplicate blood cultures from the same bacteraemia episode (7days between positives
             with the same organism, or 24h for different organisms)

          -  Patients from who blood cultures are drawn on Friday evening (17h) or Saturday during
             intervention periods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inge C Gyssens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inge C Gyssens, MD, PhD</last_name>
    <phone>+3211337660</phone>
    <email>inge.gyssens@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valentino D'Onofrio, MSc</last_name>
    <phone>+3211337668</phone>
    <email>valentino.donofrio@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jessa Hospital</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentino D'Onofrio, MSc</last_name>
      <phone>+3211337668</phone>
      <email>valentino.donofrio@uhasselt.be</email>
    </contact>
    <contact_backup>
      <last_name>Inge C Gyssens, MD, PhD</last_name>
      <phone>+3211337660</phone>
      <email>inge.gyssens@jessazh.be</email>
    </contact_backup>
    <investigator>
      <last_name>Inge C Gyssens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Messiaen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reinoud Cartuyvels, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnes Meersman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johan Vanwalleghem, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentino D'Onofrio, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</citation>
    <PMID>26903338</PMID>
  </reference>
  <reference>
    <citation>Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M; Sepsis Definitions Task Force. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):775-87. doi: 10.1001/jama.2016.0289. Review.</citation>
    <PMID>26903336</PMID>
  </reference>
  <reference>
    <citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18.</citation>
    <PMID>28101605</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>prof. dr. Inge Gyssens</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

